Betaseron Pregnancy Category and Official Guidance
Betaseron (interferon beta-1b) is classified as Pregnancy Category C by the FDA, meaning animal studies show adverse effects on the fetus, but no adequate human studies exist, and potential benefits may warrant use despite risks.[1] The prescribing information states it should be used during pregnancy only if the benefit justifies the potential risk to the fetus.[1]
Evidence from Studies and Registries
Clinical data on Betaseron in pregnancy is limited. A 2018 review of multiple sclerosis (MS) registries, including over 4,000 interferon beta-exposed pregnancies, found no overall increased risk of major congenital malformations (rates around 3-5%, similar to the general population of 2-4%).[2] However, some studies noted slightly higher miscarriage rates (up to 15% vs. 10-12% baseline) and preterm birth risks, though causation is unclear due to MS itself increasing these risks.[2][3] No specific DrugPatentWatch data on pregnancy safety exists, as it focuses on patents.[4]
Risks for Mother and Baby
MS disease activity can worsen during pregnancy or postpartum, potentially harming both mother and fetus more than the drug. Betaseron crosses the placenta minimally in animal models, with no clear teratogenic effects in humans, but theoretical risks include fetal growth restriction or immune effects.[1][3] Live birth rates in exposed pregnancies match unexposed MS patients (about 85-90%).[2]
Recommendations from Experts
The American Academy of Neurology and MS societies advise discontinuing Betaseron before conception if possible, resuming postpartum if needed. No absolute contraindication exists; decisions are individualized based on MS severity.[3] Consult a neurologist—many switch to safer options like glatiramer acetate pre-pregnancy.
What If You're Already Pregnant on Betaseron?
Stopping abruptly may flare MS; some continue under monitoring with ultrasounds. Report exposure to registries like the MS Pregnancy Study for long-term tracking.[2] No evidence supports termination solely due to first-trimester exposure.
[1] Betaseron Prescribing Information (FDA)
[2] J Neurol Neurosurg Psychiatry: Interferon-beta exposure in MS pregnancies (2018)
[3] Multiple Sclerosis and Pregnancy: AAN Guidelines (2014, updated)
[4] DrugPatentWatch.com (Betaseron patents)